Webster N R, Galley H F
Anaesthesia and Intensive Care, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK.
Br J Anaesth. 2009 Jul;103(1):70-81. doi: 10.1093/bja/aep128. Epub 2009 May 27.
Immunotherapy in the critically ill is an appealing notion because of the apparent abnormal immune and inflammatory responses seen in so many patients. The administration of a medication that could alter immune responses and decrease mortality in patients with sepsis could represent a 'magic bullet'. Various approaches have been tried over the last 20 yr: steroids; anti-endotoxin or anti-cytokine antibodies; cytokine receptor antagonists; and other agents with immune-modulating side-effects. However, in some respects, research along these lines has been unsuccessful or disappointing at best. The current state of knowledge is summarized with particular reference to sepsis and the acute respiratory distress syndrome.
鉴于众多重症患者存在明显异常的免疫和炎症反应,重症患者的免疫治疗是一个颇具吸引力的概念。给予一种能够改变免疫反应并降低脓毒症患者死亡率的药物可能堪称“神奇子弹”。在过去20年里已经尝试了各种方法:类固醇;抗内毒素或抗细胞因子抗体;细胞因子受体拮抗剂;以及其他具有免疫调节副作用的药物。然而,在某些方面,这类研究充其量只是不成功或令人失望。本文特别参照脓毒症和急性呼吸窘迫综合征总结了当前的知识状况。